SCHEMBL7648946

SCHEMBL7648946

O=C(O)[C@H]1CCCCCN1C(=O)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PREP P48147 3/20 0.61
FKBP1A P62942 2/20 0.58
CTRB1 P17538 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
ALDH1A1 P00352 1/20 0.57
NPSR1 Q6W5P4 1/20 0.56
CTSB P07858 1/20 0.56
CTSS P25774 1/20 0.56
CTSK P43235 1/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
TSHR P16473 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
KMT2A Q03164 1/20 0.55
KLK7 P49862 1/20 0.55
KLK5 Q9Y337 1/20 0.55
KDM4E B2RXH2 1/20 0.55
LMNA P02545 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7650461 1.00 PREP (0.61) PREPFKBP1ACTRB1SMN1; SMN2ALDH1A1
SCHEMBL7648948 1.00 PREP (0.61) PREPFKBP1ACTRB1SMN1; SMN2ALDH1A1
SCHEMBL630241 0.99 PREP (0.62) PREPFKBP1ACTRB1SMN1; SMN2ALDH1A1
SCHEMBL630208 0.99 PREP (0.62) PREPFKBP1ACTRB1SMN1; SMN2ALDH1A1
SCHEMBL82714 0.99 PREP (0.62) PREPFKBP1ACTRB1SMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL29077433 0.97 PREP (0.61) PREPFKBP1ACTRB1SMN1; SMN2ALDH1A1
SCHEMBL29553 0.94 PREP (0.67) PREPCTRB1SMN1; SMN2ALDH1A1NPSR1
SCHEMBL205223 0.94 PREP (0.67) PREPCTRB1SMN1; SMN2ALDH1A1NPSR1
SCHEMBL29658848 0.94 PREP (0.67) PREPCTRB1SMN1; SMN2ALDH1A1NPSR1
SCHEMBL475715 0.94 PREP (0.67) PREPCTRB1SMN1; SMN2ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11274100-B2 EP300/CREBBP inhibitor DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-03-15 US disclosed
US-20210171520-A1 EP300/CREBBP INHIBITOR DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-06-10 US disclosed
US-20210171520-A1 EP300/CREBBP INHIBITOR DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-06-10 US disclosed
EP-3643703-A1 EP300/CREBBP INHIBITOR Daiichi Sankyo Co., Ltd. (JP) 2020-04-29 EP disclosed
US-6479480-B1 1H-INDOLE DERIVATIVES BEARING AN OPTIONALLY SUBSTITUTED PHENYL MOIETY AT THE 2-POSITION OF THE INDOLE RING SYSTEM AND A METHYLENE-LINKED HETEROCYCLIC MOIETY AT THE 3-POSITION OF THE INDOLE RING SYSTEM; SCHIZOPHRENIA TREATMENT MERCK SHARP & DOHME LTD. (GB) 2002-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274100-B2 EP300/CREBBP inhibitor EP300, CREBBP, CREB1 PREP 3546/4885FKBP1A 3445/4885CTRB1 3519/4885
US-20210171520-A1 EP300/CREBBP INHIBITOR EP300, CREBBP, CREB1 PREP 3546/4885FKBP1A 3445/4885CTRB1 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.